Photo via Fast Company
In a significant shift in federal drug policy, the Trump administration has announced plans to reclassify certain forms of marijuana from Schedule I—the same category as heroin and LSD—to Schedule III, according to Fast Company. The Department of Justice will immediately move state-licensed and FDA-approved cannabis products to a classification reserved for substances with moderate to low abuse potential, a move that acknowledges evolving scientific understanding of the drug's medical applications.
The reclassification decision accelerates momentum from the Biden administration's 2023 recommendation and represents a pivotal moment for the cannabis industry, which has struggled under federal restrictions despite operating legally in 40 states for medical use and 24 states for recreational purposes. The DOJ has scheduled an expedited hearing for June to potentially fast-track further rescheduling efforts, signaling the administration's commitment to reforming cannabis policy alongside broader psychedelic drug research initiatives.
For cannabis businesses in North Carolina and across the Southeast, the practical implications remain complex. While the reclassification won't immediately legalize marijuana federally or eliminate interstate commerce restrictions, it could pave the way for significant tax relief. Currently, cannabis companies face effective tax rates as high as 70% due to Section 280E of the IRS code, which prohibits tax deductions available to other industries—a substantial burden that reclassification could help alleviate.
However, meaningful tax relief won't happen automatically. The IRS will need to reinterpret how Section 280E applies to Schedule III cannabis products, a process that could take months. For an industry facing inventory gluts, stagnant demand, and declining prices, this federal reclassification represents a rare opportunity for regulatory and financial relief, though state-level legal frameworks will continue to shape local business operations.
